Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab
demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …

7519 Background: To compare the efficacy of MTA and ERL as second-line treatment of
patients with advanced/metastatic NSCLC. Methods: Pts were randomized either to MTA …

BACKGROUND: Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …

Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer
(NSCLC), following failure of initial therapy. Studies to define patients that derive maximal …

Aim: This study aimed to analyze whether or not the efficacy and safety of erlotinib are
influenced by differences among treatment lines and initiation timing in advanced non-small …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …

Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …

Results: Patients received erlotinib in a single dose of 150 mg per day. Partial response
(PR), stable disease (SD) or progressive disease (PD) were observ-ed in 5 (9%), 33 (59%) …

Erlotinib is an orally active inhibitor of the epidermal growth factor receptor that is effective
for the treatment of non–small-cell lung cancer (NSCLC). Patients with a poor performance …